SCHEMBL2163243

SCHEMBL2163243

CCOC(=O)c1c(NC(=O)c2c(F)cccc2F)sc2c1C(C)OC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 3/20 0.49
CXCR4 P61073 2/20 0.49
HPGD P15428 10/20 0.44
ALDH1A1 P00352 9/20 0.44
KDM4E B2RXH2 8/20 0.44
HSD17B10 Q99714 7/20 0.44
NPSR1 Q6W5P4 5/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 5/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
THRB P10828 1/20 0.44
TDP1 Q9NUW8 4/20 0.43
MAPK1 P28482 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
USP2 O75604 2/20 0.43
ALOX15 P16050 1/20 0.43
PTGER2 P43116 1/20 0.43
LMNA P02545 4/20 0.43
CASP1 P29466 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162508 0.93 CXCR2 (0.46) CXCR2CXCR4HPGDALDH1A1KDM4E
SCHEMBL2162158 0.92 CNR2 (0.52) CXCR2CXCR4HPGDALDH1A1KDM4E
SCHEMBL2162704 0.90 MAPT (0.50) CXCR2HPGDALDH1A1KDM4EHSD17B10
SCHEMBL2162571 0.88 HPGD (0.45) CXCR2HPGDALDH1A1KDM4EHSD17B10
SCHEMBL2162159 0.82 CNR2 (0.49) CXCR2CXCR4HPGDALDH1A1KDM4E
SCHEMBL2162462 0.82 CXCR2 (0.42) CXCR2CXCR4HPGDALDH1A1KDM4E
SCHEMBL2162073 0.78 KMT2A (0.51) CXCR2HPGDALDH1A1KDM4EHSD17B10
SCHEMBL2162606 0.78 ANO1 (0.43) CXCR2CXCR4HPGDALDH1A1KDM4E
SCHEMBL2163568 0.78 MAPT (0.51) CXCR2HPGDALDH1A1KDM4EHSD17B10
SCHEMBL2162342 0.77 CNR2 (0.52) ALDH1A1KDM4EMAPTLMNACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US claimed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US claimed
US-7985768-B2 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants ABBOTT LABORATORIES (US) 2011-07-26 US disclosed
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058308-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, OPRL1 CXCR2 402/4885CXCR4 466/4885HPGD 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.